BGP-15 | PARP抑制剂 | MCE

来自 : 发布时间：2024-05-14

请完善您的信息，提交审核升级会员，查看BGP-15的详细信息 完成审核- 升级您的专属账户 即刻兑换价值 500 积分的多种礼券 根据当地政策法规的要求，该产品仅对科研客户提供相关信息。 您需要登录/注册您的专属账户，或与客服人员直接联系 确认您的产品用途，通过审核后，即可查看MCE会员专属产品。 1.客户无需承担相应的运输费用。 2.同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内 可免费申领三个不同产品的试用装。 3.试用装只面向终端客户。 BGP-15 (200 μM) prevents the imatinib mesylate-induced oxidative damages, attenuates the depletion of high-energy phosphates, alters the signaling effect of imatinib mesylate by preventing p38 MAP kinase and JNK activation, and induced the phosphorylation of Akt and GSK-3beta[5]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. BGP-15 (15 mg/kg, p.o.) does not improve skeletal muscle pathology in older mdx mice[1]. In a rat model, 10 days of BGP-15 treatment greatly improves diaphragm muscle fiber function (by about 100%), although it does not reverse diaphragm atrophy. The treatment also provides protection from myosin PTMs associated with HSP72 induction and PARP-1 inhibition, resulting in improvement of mitochondrial function and content[2]. BGP-15 (15 mg/kg per day in saline) treatment has no effect in Ntg mice or an independent cohort of normal adult wild-type mice based on morphology, cardiac function and ECG parameters. Treatment with BGP-15 attenuates the increase in atrial size and lung weight. BGP-15 treatment is able to prevent or reduce episodes of arrhythmia. BGP-15 treatment is associated with a reduced PR interval in the HF+AF model[3]. BGP-15 (10 and 30 mg/kg) increases insulin sensitivity by 50% and 70%, respectively, in cholesterol-fed but not in normal rabbits. After 5 days of treatment with BGP-15, the glucose infusion rate is increased in a dose-dependent manner in genetically insulin-resistant GK rats. The most effective dose is 20 mg/kg, which shows a 71% increase in insulin sensitivity compared to control group[4]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂： ——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶 请依序添加每种溶剂：10% DMSO40% PEG3005% Tween-8045% salineSolubility: ≥ 2.5 mg/mL (7.12 mM); Clear solution 此方案可获得 ≥ 2.5 mg/mL (7.12 mM，饱和度未知) 的澄清溶液。以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液 请依序添加每种溶剂：10% DMSO90% (20% SBE-β-CD in saline)Solubility: ≥ 2.5 mg/mL (7.12 mM); Clear solution 此方案可获得 ≥ 2.5 mg/mL (7.12 mM，饱和度未知) 的澄清溶液。以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明 请依序添加每种溶剂：10% DMSO90% corn oilSolubility: ≥ 2.5 mg/mL (7.12 mM); Clear solution 此方案可获得 ≥ 2.5 mg/mL (7.12 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。 Adult (appr 4 month) male HF+AF and Ntg mice are administered with BGP-15 (15 mg/kg per day in saline) for 4 weeks by oral gavage or remained untreated (oral gavage with saline or no gavage). Gavage with saline has no effect on morphological or functional parameters in the HF+AF model. Therefore, untreated mice (no gavage) and mice administered saline are combined and referred to as HF+AF control. Echocardiography and ECG studies are performed before and after treatment. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Concentration (start) × Volume (start) = Concentration (final) × Volume (final) This equation is commonly abbreviated as: C1V1 = C2V2 Keywords: BGP-15BGP15BGP 15PARPpoly ADP ribose polymeraseInhibitorinhibitorinhibit Please fill out this form to request the QC report. We will send it to your Email address shortly. Your information is safe with us. * Required Fields. MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。 站点地图 隐私声明